Novo Nordisk A/S (NYSE:NVO) Holdings Raised by Verde Capital Management

Verde Capital Management increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 115.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,904 shares of the company’s stock after purchasing an additional 12,815 shares during the quarter. Novo Nordisk A/S accounts for about 0.6% of Verde Capital Management’s investment portfolio, making the stock its 29th largest holding. Verde Capital Management’s holdings in Novo Nordisk A/S were worth $2,056,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC boosted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S during the third quarter valued at approximately $98,765,000. Wellington Management Group LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $42,017,000. Finally, Sanctuary Advisors LLC acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at approximately $41,646,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $81.36 on Friday. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15. The firm has a market capitalization of $365.09 billion, a PE ratio of 26.33, a P/E/G ratio of 0.89 and a beta of 0.45. The company’s 50 day simple moving average is $96.10 and its 200 day simple moving average is $115.79. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent research reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.